Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the
more elderly population, is independently more resistant to cytotoxic chemotherapy, has a …

Objective The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes
of dose-escalated radiotherapy should be advantageous. We report our experience using …

PURPOSE: To provide a retrospective analysis of the efficacy of hyperbaric oxygen therapy (HBOT)
for treating hemorrhagic cystitis (HC) and proctitis secondary to pelvic- and prostate-…

Opinion statement Acute myelogenous leukemia (AML) in the elderly is complex and has a
poor prognosis, often characterized by higher risk cytogenetic and molecular features …

Introduction: Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody
that targets CD19. L-MIND (NCT02399085) is an ongoing, open-label, single-arm, phase II …

Tisagenlecleucel (tisa-cel) is an approved CD19-directed chimeric antigen receptor T cell (CAR-T)
therapy for relapsed/refractory B cell malignancies. Given potentially life-threatening …

Checkpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after …

Autologous CD19/CD20 bispecific CAR-T cell therapy generated from T N/MEM cells for
patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and …

Although much is known about the initiation of immune responses, much less is known about
what controls the effector phase. CD8+ T cell responses are believed to be programmed in …

Purpose Pseudocirrhosis has been demonstrated to mimic cirrhosis radiographically, but
studies evaluating the pathophysiology and clinical features are lacking. To better understand …